Wu X, Liszewski M, Java A, Atkinson J
Ann Blood. 2025; 8.
PMID: 39949759
PMC: 11824723.
DOI: 10.21037/aob-22-40.
Korzycka J, Pawlowicz-Szlarska E, Masajtis-Zagajewska A, Nowicki M
Am J Case Rep. 2022; 23:e936565.
PMID: 36306276
PMC: 9623542.
DOI: 10.12659/AJCR.936565.
Hourcade D, Akk A, Mitchell L, Zhou H, Hauhart R, Pham C
Mol Immunol. 2015; 69:62-9.
PMID: 26675068
PMC: 4698246.
DOI: 10.1016/j.molimm.2015.11.008.
Bertram P, Akk A, Zhou H, Mitchell L, Pham C, Hourcade D
Monoclon Antib Immunodiagn Immunother. 2015; 34(1):1-6.
PMID: 25723276
PMC: 4350452.
DOI: 10.1089/mab.2014.0066.
Rafiq A, Tariq H, Abbas N, Shenoy R
Am J Case Rep. 2015; 16:109-14.
PMID: 25708146
PMC: 4341946.
DOI: 10.12659/AJCR.892907.
Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management.
Yenerel M
Turk J Haematol. 2014; 31(3):216-25.
PMID: 25319590
PMC: 4287021.
DOI: 10.4274/tjh.2013.0374.
Access to the complement factor B scissile bond is facilitated by association of factor B with C3b protein.
Hourcade D, Mitchell L
J Biol Chem. 2011; 286(41):35725-35732.
PMID: 21862585
PMC: 3195642.
DOI: 10.1074/jbc.M111.263418.
Why Do We Need ADAMTS13?.
Tsai H
Nihon Kessen Shiketsu Gakkai shi. 2011; 16(1):54-69.
PMID: 21709769
PMC: 3121331.
DOI: 10.2491/jjsth.16.54.
Hemolytic uremic syndrome after renal transplantation.
Vergoulas G
Hippokratia. 2010; 10(3):99-104.
PMID: 20351803
PMC: 2808399.
A clinical algorithm identifies high risk pediatric oncology and bone marrow transplant patients likely to benefit from treatment of adenoviral infection.
Williams K, Agwu A, Dabb A, Higman M, Loeb D, Valsamakis A
J Pediatr Hematol Oncol. 2009; 31(11):825-31.
PMID: 19801951
PMC: 4251427.
DOI: 10.1097/MPH.0b013e3181b7873e.
A large family with a gain-of-function mutation of complement C3 predisposing to atypical hemolytic uremic syndrome, microhematuria, hypertension and chronic renal failure.
Lhotta K, Janecke A, Scheiring J, Petzlberger B, Giner T, Fally V
Clin J Am Soc Nephrol. 2009; 4(8):1356-62.
PMID: 19590060
PMC: 2723975.
DOI: 10.2215/CJN.06281208.
Theodore E. Woodward Award: antiphospholipid syndrome revisited: a disorder initiated by inflammation.
Salmon J, Girardi G
Trans Am Clin Climatol Assoc. 2008; 118:99-114.
PMID: 18528494
PMC: 1863598.
Pathogenic role of antiphospholipid antibodies.
Salmon J, de Groot P
Lupus. 2008; 17(5):405-11.
PMID: 18490417
PMC: 2693020.
DOI: 10.1177/0961203308090025.
Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis.
Noris M, Remuzzi G
Clin Exp Immunol. 2007; 151(2):199-209.
PMID: 18070148
PMC: 2276938.
DOI: 10.1111/j.1365-2249.2007.03558.x.
Modeling how CD46 deficiency predisposes to atypical hemolytic uremic syndrome.
Liszewski M, Leung M, Schraml B, Goodship T, Atkinson J
Mol Immunol. 2006; 44(7):1559-68.
PMID: 17027083
PMC: 1828070.
DOI: 10.1016/j.molimm.2006.08.024.
Suicidal death of erythrocytes in recurrent hemolytic uremic syndrome.
Lang P, Beringer O, Nicolay J, Amon O, Kempe D, Hermle T
J Mol Med (Berl). 2006; 84(5):378-88.
PMID: 16622713
DOI: 10.1007/s00109-006-0058-0.
Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion.
Thurman J, Ljubanovic D, Royer P, Kraus D, Molina H, Barry N
J Clin Invest. 2006; 116(2):357-68.
PMID: 16444293
PMC: 1352158.
DOI: 10.1172/JCI24521.
A case of atypical hemolytic uremic syndrome with a transient decrease in complement factor H.
Hahn H, Um E, Park Y, Cheong H
Pediatr Nephrol. 2005; 21(2):295-8.
PMID: 16362720
DOI: 10.1007/s00467-005-2108-1.
Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: emerging insights for vascular integrity.
Densen P
Curr Infect Dis Rep. 2005; 7(5):319-21.
PMID: 16107226
DOI: 10.1007/s11908-005-0002-4.
Prospective surveillance of Canadian children with the haemolytic uraemic syndrome.
Proulx F, Sockett P
Pediatr Nephrol. 2005; 20(6):786-90.
PMID: 15834619
DOI: 10.1007/s00467-005-1843-7.